中源协和：治疗特发性肺纤维化适应症完成Ⅰ期所有受试者给药，正开展临床安全性、有效性数据整理

Core Viewpoint - Zhongyuan Xiehe announced that its affiliated company, Beijing Sanyouli, in collaboration with Capital Medical University, is progressing with the clinical trials of "human dental pulp mesenchymal stem cell injection" for the treatment of chronic periodontitis, with all participants for Phase II expected to be enrolled by 2024 [1] Group 1 - The company is conducting regular follow-up work for the chronic periodontitis treatment trial [1] - The treatment for idiopathic pulmonary fibrosis has completed all participant dosing in Phase I, and the company is currently organizing clinical safety and efficacy data [1]